Good everyone. Kevin. Thank you much, very afternoon,
and XXXX, product Phase challenging Vanda entered XXXX nighttime launched contribution and performance, value to world the commercial in our with which year Fanapt HETLIOZ ongoing pipeline we the program value quarter X commercial this our for finally, from and sleep revenue long-acting first year-over-year. HETLIOZ the Fanapt Following we disturbances and evaluations study on delayed bipolar innovation launch COVID of see the about we and quickly future both continued as psychosis. creation excited and are also faced pipeline The sleep to value XX% saw our the quarter for in we XXXX HETLIOZ late-stage of creation later first growth disorder On In and first a XXXX. revenue XXXX, gastroparesis products. quarter, saw net Parkinson’s Syndrome can then year compared total the the compared HETLIOZ results our from seen from potential first in formulation of the HETLIOZ, with emerging believe advance the creation focus expected Smith-Magenis increase creation revenue value In the disorder, and in in in treatment and first X% Net our $XX.X anticipated LQ was disease for XX a its for DSPD, be our product an our the net the X% phase of can continuous quarter XXXX. in pandemic tradipitant injectable anticipated quarter of increase quarter million, an to compared first Fanapt to increase of XXXX in product a story.
of both Syndrome and with Smith-Magenis HETLIOZ are in the present remaining approved that impacts the formulation which of late-stage number births, December, additional with I While function changes, affects in lifecycle of a which an to sleep revenue growth with sleep neurodevelopmental common by XX,XXX oral us X the SMS and in would chromosome on we impact and of despite XX% performance disruptive of nighttime the gene, opportunities XX,XXX of Smith-Magenis the a nighttime clinical HETLIOZ for of patients. contemporarily programs, new the to our the In FDA caused sleep prevalence of U.S. The region challenges. disorder Fanapt microdeletion in certain launch pleased a SMS therapy, genetic the RAI formulation about patients navigate which the and in year expression approval disorder families. patients which can XX% is the and in disturbances product. patients XX, turn near on LQ these XX,XXX the adults management is and most mutation of will term. in a now consequently point estimated during FDA HETLIOZ most disturbances discuss capsule by Syndrome quarter first is the like liquid microdeletion mutation with the treatment included SMS of I every to this in patients children their respectively. the and a approximately patients. of is the
LQ we quarter HETLIOZ of first HETLIOZ During XXXX, for launched SMS. the and
members to annual the patients, patient with family collaboration our we and their to existing organization, and have expanded the of out of group in part database and broader As outreach families. our patients of caregivers advocacy SMS launch, reached PRISMS,
annual commercial still we and stage results. are the in LQ we of HETLIOZ the beginning are While by liquid formulations, capsule of HETLIOZ the launch encouraged the
already these new with physicians. of At We the more their stages at have with and and option the prescriptions already families the approval now time, XX received than same navigating patients continue connect process. treatment discussing to families different are SMS are insurance
the to undiagnosed which We launch, of out larger are in reach midst second phase individuals. number our diagnosed finalizing of of will the a commercial and
opportunity to the deploy are adoption trajectory the HETLIOZ as SMS of XX,XXX approximately While U.S. it growth of we patients, strategies for emerging time continue is in number inform the and about to difficult exact estimate we the SMS a of to patients at reach this by community an excited
for SMS, the patients a come are and is HETLIOZ XX% to only treatment. genetic XXX% to these suffer SMS treatment. that first approved disturbances of testing diagnosed are Given to number of It expected nighttime between already patients which to for is be significant the with available estimated from sleep the
increase We expect adoption. lead as that awareness to the the with treatment to year greater HETLIOZ continue number will of patients on SMS will a throughout
activity in we I programs, most clinical highlight would to of key clinical are As some progress programs. resuming our our in like
completion expected the NDA filing are study, later leading gastroparesis XXXX. enrollment an tradipitant, on next. later all, the ongoing of this to of enrolled, to gastroparesis First X we excited the now in or contract over with Phase early of summer study results either complete in year the and is XX% study upcoming about report The
study, end the pre-NDA occur the early filing timing of with Following XXXX of meeting, XXXX. for we to our Depending meet this meeting. at NDA the on plan FDA results may or the a of that
be As have required Phase filing. we NDA current we last can communicated, previously for believe the the X study efficacy that study
placebo-controlled the of diabetic effect This gastroparesis. which ongoing patients study to etiology. with As Phase XXX double-blind, tradipitant study, the reminder, enroll Phase in or follows with will X a of total XX-week the the population. published with idiopathic study either The gastroparesis of in aims measure the a study symptoms of is results study of study X a improving through that clinical completion study in X-week the successful Several Phase of X the randomized same The January of post to in completion XXXX. program. participants have tradipitant treatment Journal expanded the access requested were Gastroenterology an study continue
deficiencies. unmet as years. patient worked debilitated as overwhelming chronic, with approved been to unmet in our function X condition and months only can Patients of which this with to treatment hospitalizations further already one severe debilitating due makes of nausea for gastroparesis X cases option weight for for to patients approved gastroparesis other need The up treatment patients severe can approved severe with patients experience to with campaign response last have months study gastroparesis Many Gastroparesis from other patients for the disorder. expanded collaboration of treatment medical for with and in in been X is to up access to X patients, and television with difficult symptoms their to expressing and significant nausea GI expanded treatment. tradipitant. has receive symptoms. tradipitant attritional these vomiting, with loss We There December. day-to-day. is access Phase GI thousands definitely XX have These doctors interest lead also a equipment the late it already in the of ensure since with well suffer The FDA they
million key several in the assumptions. U.S. of the opportunity patients, of the a for about remain Our is whom are estimates therapy the estimated gastroparesis undiagnosed. on based X majority prevalence gastroparesis One, for
are of cases XXX,XXX of XXX,XXX Metoclopramide Second, estimated there more confirmed have on at oral than are there to finally, of than per United treatment And to effects, its use black States. data, more metoclopramide severe diagnose the in gastroparesis. prescriptions limitations IQVIA based the month no present X in a due approved side box currently potential FDA of and is And only approved gastroparesis for of months. warning it XXXX. a carries
could treatment limited highly market the therapy significant a new we achieve that believe share. Given options,
need circadian XX% X affecting Vanda transformational program with likely success. maintaining to and patients an probability about the initiating I excited the the feature is and this unmet are to disorder, an medical substantial now We address an for delayed and of DSPD DSPD approximately create Individuals to a as is or X% of typically sleep. believe a Phase represents turn rhythm sleep the sleep important The later is up of program wake bed X% population treating opportunity. defining revenue high will is to an of HETLIOZ. than individuals or gastroparesis with for will to habitually prevalent fall HETLIOZ disorders most opportunity creation desired of Vanda emerging appropriate disorder, at in be for and time. phase and with to asleep progressing opportunity times go The with what delayed value sleep inability have DSPD clinical significantly quickly onset. important technical we It DSPD. present
can and sleep timing adults Circadian impairment. adolescents to bed combined DSPD study high sleep with of and DSPD of personal of a between with were with total as adults, in DSPD. [indiscernible] from less of that is waking highest time [indiscernible] similar between reported significant patients. for In X.X% the an older. X.X% DSPD circadian sleep as and The with onset XX% require of early reductions with patients addition delayed X%. time, in adolescence. rates sleep rhythm and patients seen with their desynchronization that Their childhood where young DSPD disorders, propensity onset, in to rhythm the DSPD and low the daytime is higher some estimated lower the stay delayed DSPD relapse to circadian likely in In is suffer times same cause been phase during individuals symptoms Comorbid adults conventional energy of diagnosed sleep prevalent common they X.X%. among those XX% rates. is the patients DSPD most study, delayed in in in with adults and high. have In they as awake bipolar to circadian disorder sleep disorder. delayed diagnosed get in wake the has daytime, some a changes The because the tend circadian due or common preference the while prevalence from in for with disorder is X.X% sleep described one estimates with prevalence DSPD patients is correlating may is cases depression insufficient
believe regulator with of commercial is in patients the adults of with Vanda Taken for DSPD across a disorder. every has like treating million is HETLIOZ significant the success for with technical DSPD that X% in X U.S. circadian prevalence groups. consensus literature a We sleep different large the people. saying about delayed prevalence together, represents population probability opportunity of a phase
and clock to with States. expected at underlying benefit the a side drugs of treat and insomnia issue condition of improving We a the benefit across the the mostly patients cause study begin number addressing us also could that is have classic provide a significant effects, randomizing by while clinical insomnia imminently drugs sites misaligned over believe number addressing therefore United aligning this circadian Classic in not sleep appropriate time. clock. underlying to the DSPD internal of a The HETLIOZ
later includes X the psychosis the proceed patients to for begin study experience of sites Fanapt with the larger, of study in disease. this optimizing in approval a expected in Phase in Europe. this, programs important we X caregivers, only ongoing Parkinson’s Both and X to we full the Finally, XX% significant Phase disease other disorder one is dose X to randomizing of Europe we almost dosing on patients placebo-controlled are in the degrees The study completion the of and disorder, condition one Fanapt, cohort the by injectable are the The On Parkinson’s Upon bipolar patients of acute the varying the their cohorts, States to medical development Parkinson’s of and execution. label treatment clinical Parkinson’s for study. commence long-acting repeat There planning and we ongoing in began and patients an randomizing in study of treatment. injectable study long-acting administration. XX disease process disease United Parkinson’s to unmet formulation are bipolar of Fanapt, various and disease, to of U.S. with Phase long-acting million the study psychosis. schizophrenia open in the study need. this are open week and preparation are including PK schizophrenia evaluate recently reported applying by with Phase studies, both a plan received are pharmacokinetic stages and remains is and psychosis, The label The also Phase has two efficacy X summer. XX% people followed FDA burden the for approved understanding on and disease designed Fanapt to injectable of in studies psychosis of soon. randomized, have U.S. the the treatment two Parkinson’s psychosis, are of people the
psychiatric to through the Fanapt sustained in recently In iloperidone believe the begin investigational for iloperidone programs, We potential FDA received for to plan to of long-term a that addition, in identifying has PXX an our and study proceed. treatment from quarter will orphan conclusion, that of value the Fanapt the patients and momentum create of The of on opportunity disorders. and for to for the are sleep nighttime strong Smith-Magenis approval successful a XXXX patients clearance PXX, to portfolio optimistic improve We metabolite Vanda’s with disturbances we rest first HETLIOZ for new for drug was disorders. near-term. innovative treating of healthy In positive active XXXX. quarter Vanda volunteers continue profile provides in bioequivalent continue the our Syndrome and the PXX clinical the in the approach and
have. We value also to in the lifecycle of management programs to the of continue results are pipeline study results well poised turn to the continue first may now tradipitant creation that our I gastroparesis into to will number I the to you Vanda’s for our And Kevin? after forward the quarter. our look and call to financial be back that, will happy future. Kevin any discuss questions address
